US › Healthcare

Neumora Therapeutics, Inc. (NMRA)

US · Healthcare · Biotechnology

$0.47+11.01%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-43.1M

EPS

$-0.23

EPS estimate

$-0.23

EPS came in at -0.23 against a street estimate of -0.23 — a beat of 0.0%.

Key statistics

Market cap

$66.6M

Forward P/E

0.0

P/B

3.09

Book value

$0.24

EPS (TTM)

$-1.23

52-week high

$3.65

52-week low

$0.32

50-day MA

$1.08

200-day MA

$1.87

Beta

2.98

Analyst view

Analysts rate Neumora Therapeutics, Inc. a buy (7 buy, 1 hold, 1 sell out of 9) with an average price target of $6.14.

Shareholding

Insiders

23.08%

Institutions

60.14%

Largest institutional holders

Fund	Stake
Siren, L.L.C.	4.52%
BlackRock Inc	4.15%
SoftBank Group Corp	3.24%
Vanguard Capital Management, LLC	2.49%
MIC Capital Management UK LLP	2.37%
FMR Inc	1.86%
Wellcome Trust Ltd	1.76%
Geode Capital Management, LLC	1.39%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neumora Therapeutics, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.